Patisiran (an RNA interference drug that lowers TTR production) improves neuropathy and quality of life in hereditary ATTR (phase 3); approved.
Confidence
Established
Level of evidence
●●●●●● Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisPatisiranTransthyretin amyloidosis (ATTR)
What the sources say
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).